Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases (GMX07)

A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases

The primary objective is to demonstrate the bioequivalence of Gammaplex® 10 intravenous immunoglobulin (IGIV) and Gammaplex® 5% IGIV with respect to area under the curve within a 28-day dosing interval (AUC0-28) in a cohort of adult subjects.

The secondary objectives are to demonstrate the bioequivalence of Gammaplex® 10 IGIV and Gammaplex® 5% IGIV with respect to area under the curve within a 21-day dosing interval (AUC0-21) in adult subjects; to assess the pharmacokinetics of Gammaplex 10 IGIV and Gammaplex 5% IGIV including Immunoglobulin G (IgG) trough levels and to investigate the safety and tolerability of Gammaplex 10 IGIV and Gammaplex 5% IGIV in adults subjects; to assess the pharmacokinetics of Gammaplex 10 IGIV including IgG trough levels and to investigate the safety and tolerability of Gammaplex 10 IGIV in pediatric subjects.

Study Overview

• Status: Completed
• Conditions: Common Variable Immunodeficiency; Primary Immune Deficiency Disorders; Hyper-IgM Syndrome; X-linked Agammaglobulinaemia
• Intervention / Treatment: Biological: Gammaplex (5%); Biological: Gammaplex 10

• Study Type: Interventional
• Enrollment (Actual): 48
• Phase: Phase 3

Contacts and Locations

Study Locations

• Hungary
  • Budapest, Hungary
    • Egyesített Szent István és Szent László Kórház
• United Kingdom
  • London, United Kingdom, NW3 2QG
    • The Royal Free Hospital and Medical School
  • Wales
    • Cardiff, Wales, United Kingdom, CF14 4XW
      • University Hospital of Wales
• United States
  • Arizona
    • Chandler, Arizona, United States, 85224
      • Arizona Allergy Associates
  • California
    • Long Beach,, California, United States, 90806
      • Miller Children's Hospital
    • Los Angeles, California, United States, 90027
      • Childrens Hospital Los Angeles
    • Los Angeles,, California, United States, 90095
      • UCLA Medical Center
  • Colorado
    • Centennial, Colorado, United States, 80112
      • IMMUNOe International Research Centers
  • Florida
    • Hollywood, Florida, United States, 33021
      • Joe DiMaggio Children's Hospital
    • N Palm Beach, Florida, United States, 33408
      • Allergy Associates of The Palm Beaches, PA
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Rush University Medical Center
  • Maryland
    • Chevy Chase, Maryland, United States, 20815
      • Institute for Asthma and Allergy
  • Ohio
    • Toledo, Ohio, United States, 43617
      • Asthma and Allergy Center
  • Texas
    • Dallas, Texas, United States, 75230
      • Dallas Allergy Immunology Research
  • Utah
    • Salt Lake City, Utah, United States, 84113
      • University of Utah Primary Children's Hospital
  • Virginia
    • Fairfax,, Virginia, United States, 22030
      • O&O Alpan, LLC
  • Washington
    • Bellingham, Washington, United States, 98225
      • Bellingham Asthma Allergy and Immunology Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years to 55 years (ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion criteria:

1. Adult cohort: The subject is aged 16 to 55 years inclusive, is of either sex, and belongs to any ethnic group.

   Pediatric cohort: The subject is aged 2 to 15 years inclusive, is of either sex, weighs at least 10 kg, and belongs to any ethnic group.

2. The subject has primary immunodeficiency disease, e.g. common variable immunodeficiency, X linked and autosomal forms of agammaglobulinemia, hyper IgM (Immunoglobulin M) syndrome. Isolated deficiency of a single IgG subclass or of specific antibodies without hypogammaglobulinemia per se, does not qualify for inclusion.
3. The subject is currently receiving a licensed IGIV (or investigational stage III, IIIb IGIV) at a dose that has not changed by ± 50% of the mean dose for at least three months before study entry and is between 300 and 800 mg/kg/infusion. The infusion interval must be either every 21 or every 28 days.
4. The subject must have a trough level ≥ 6 g/L (600 mg/dL). At least one documented trough level must be available from the three months before Screening.
5. The subject must have documentation from the last three consecutive routine IGIV infusions for the following, before the first infusion in this study: dose of IGIV, treatment intervals, and trade name (or identity) of the IGIV treatment.
6. Female subjects of childbearing potential must have a negative result on an HCG (human chorionic gonadotropin) based pregnancy test at Screening.
7. Females who are or become sexually active must practice contraception using a method of proven reliability for the study duration.
8. The subject is willing to comply with all aspects of the protocol for the duration of the study.
9. The subject has signed an informed consent form and assent form (if applicable).

Exclusion criteria:

1. The subject has a history of any severe anaphylactic reaction to blood or any blood derived product.
2. The subject has selective IgA deficiency, history of reaction to products containing IgA (Immunoglobulin A), or has a history of antibodies to IgA.
3. The subject has cellular or innate impaired immunity (i.e. only subjects with humoral impaired immunity may be included).
4. The subject has evidence of an active infection at the time of enrolment.
5. The subject has previously completed or withdrawn from this study.
6. The subject is currently receiving, or has received, any investigational agent other than an IGIV within the prior three months.
7. The subject is pregnant or is nursing.

8. The subject has positive results for any of the following at Screening:

   • Serological test for HIV 1 and 2, HCV, or HBsAg
   • NAT (Nucleic acid amplification technique)for HCV
   • NAT for HIV

9. The subject has levels > 2.5 times the upper limit of normal, as defined at the central laboratory, of any of the following at Screening:

   • Alanine amino transaminase
   • Aspartate amino transaminase
10. The subject has severe renal impairment (defined as serum creatinine greater than two times the upper limit of normal or blood urea nitrogen greater than 2.5 times the upper limit of normal for the range of the laboratory doing the analysis); the subject is on dialysis; the subject has a history of acute renal failure.
11. The subject is known to abuse alcohol, opiates, psychotropic agents, or other chemicals or drugs, or has done so within the past 12 months.
12. The subject has a history of deep vein thrombosis or thrombotic complications of IGIV therapy.
13. The subject suffers from any acute or chronic* medical condition (e.g. renal disease or predisposing conditions for renal disease, coronary artery disease, or protein losing state) that the Investigator feels may interfere with the conduct of the study.
14. The subject has an acquired immunodeficiency condition such as chronic* lymphocytic leukemia, lymphoma, multiple myeloma, or chronic or recurrent neutropenia (absolute neutrophil count < 1 × 109/L).

15. The subject is receiving the following medication:

    • Steroids (long term daily, ≥ 0.15 mg of prednisone equivalent/kg/day). Requirement for short or intermittent courses of steroids would not exclude a subject.
    • Immunosuppressive drugs
    • Immunomodulatory drugs
16. The subject has uncontrolled arterial hypertension (systolic blood pressure > 160 mm Hg and/or diastolic blood pressure > 100 mm Hg).
17. The subject has anemia (hemoglobin < 10 g/dL) at Screening.

18. The subject is known to be intolerant to any component of Gammaplex, such as sorbitol (i.e. hereditary intolerance to fructose) or glycine.

    • Chronic conditions would be as per the Investigator's opinion however for this study the guidance is that the condition has been present for at least 6 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Treatment Sequence 1 - Adults; Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days	Biological: Gammaplex (5%); Biological: Gammaplex 10
EXPERIMENTAL: Treatment Sequence 2 - Adults; Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days	Biological: Gammaplex (5%); Biological: Gammaplex 10
EXPERIMENTAL: Pediatrics; Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days	Biological: Gammaplex 10

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Primary Bioequivalence Analysis - Area Under the Curve Within a 28-day Dosing Interval (AUC0-28) in Adult Subjects	After a minimum 5 infusions on each product, at pre-infusion, 10 minutes before end of infusion, 1, 3, 6, 24, 48 hours, 4, 7, 14, 21 and 28 days post-infusion

Secondary Outcome Measures

Outcome Measure	Time Frame
Secondary Bioequivalence Analysis - Area Under the Curve Within a 21-Day Dosing Interval (AUC0-21) in Adult Subjects	After a minimum 5 infusions on each product, at pre-infusion, 10 minutes before end of infusion, 1, 3, 6, 24, 48 hours, 4, 7, 14 and 21 days post-infusion
Secondary Bioequivalence Analysis - IgG Trough Levels	After a minimum 5 infusions on each product, at pre-infusion.

Collaborators and Investigators

• Sponsor: Bio Products Laboratory

Study record dates

Study Major Dates

• Study Start: February 1, 2014
• Primary Completion (ACTUAL): January 1, 2016
• Study Completion (ACTUAL): May 1, 2016

Study Registration Dates

• First Submitted: September 13, 2013
• First Submitted That Met QC Criteria: October 11, 2013
• First Posted (ESTIMATE): October 16, 2013

Study Record Updates

• Last Update Posted (ACTUAL): March 29, 2017
• Last Update Submitted That Met QC Criteria: February 10, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Hematologic Diseases; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Blood Protein Disorders; Dysgammaglobulinemia; Immunologic Deficiency Syndromes; Primary Immunodeficiency Diseases; Agammaglobulinemia; Common Variable Immunodeficiency; Hyper-IgM Immunodeficiency Syndrome; Hyper-IgM Immunodeficiency Syndrome, Type 1; Physiological Effects of Drugs; Immunologic Factors; Immunoglobulins, Intravenous; gamma-Globulins; Rho(D) Immune Globulin
• Other Study ID Numbers: GMX07